Cargando…
Tocilizumab in COVID-19: finding the optimal route and dose
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498201/ https://www.ncbi.nlm.nih.gov/pubmed/32964209 http://dx.doi.org/10.1016/S2665-9913(20)30334-9 |
| _version_ | 1783583459277537280 |
|---|---|
| author | Jain, Siddharth Jain, Sanjay Sharma, Shefali Khanna |
| author_facet | Jain, Siddharth Jain, Sanjay Sharma, Shefali Khanna |
| author_sort | Jain, Siddharth |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7498201 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74982012020-09-18 Tocilizumab in COVID-19: finding the optimal route and dose Jain, Siddharth Jain, Sanjay Sharma, Shefali Khanna Lancet Rheumatol Correspondence Elsevier Ltd. 2020-12 2020-09-17 /pmc/articles/PMC7498201/ /pubmed/32964209 http://dx.doi.org/10.1016/S2665-9913(20)30334-9 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Correspondence Jain, Siddharth Jain, Sanjay Sharma, Shefali Khanna Tocilizumab in COVID-19: finding the optimal route and dose |
| title | Tocilizumab in COVID-19: finding the optimal route and dose |
| title_full | Tocilizumab in COVID-19: finding the optimal route and dose |
| title_fullStr | Tocilizumab in COVID-19: finding the optimal route and dose |
| title_full_unstemmed | Tocilizumab in COVID-19: finding the optimal route and dose |
| title_short | Tocilizumab in COVID-19: finding the optimal route and dose |
| title_sort | tocilizumab in covid-19: finding the optimal route and dose |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498201/ https://www.ncbi.nlm.nih.gov/pubmed/32964209 http://dx.doi.org/10.1016/S2665-9913(20)30334-9 |
| work_keys_str_mv | AT jainsiddharth tocilizumabincovid19findingtheoptimalrouteanddose AT jainsanjay tocilizumabincovid19findingtheoptimalrouteanddose AT sharmashefalikhanna tocilizumabincovid19findingtheoptimalrouteanddose |